Vancouver, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The global microarray analysis market size was USD 4.90 Billion in 2022 and is expected to register a rapid revenue CAGR of 9.0% during the forecast period. A recent market research report identifies rising government initiatives in genomic and proteomic research, coupled with the broadening applications of microarray technology, as key drivers fueling this growth.
Microarray technology, a gene expression and mapping analysis tool, utilizes glass slides containing thousands of gene sequences. The technology's applications range from antibiotics treatment efficacy to cancer diagnostics, showcasing its versatility. Notably, DNA-based microarrays have gained prominence for gene expression assessments due to cost-effectiveness and increased accessibility.
The global prevalence of cancer is a major factor propelling market growth. Microarrays, especially DNA microarrays, play a crucial role in diagnosing breast cancer by identifying mutations in genes such as Breast Cancer Gene (BRCA1) and BRCA2. The rising demand for new medications and the increasing use of microarray technologies for molecular disease identification are also contributing to the market's revenue surge.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/2628
Despite the positive trajectory, challenges such as the high cost of microarray tests and limitations in controlling large volumes of analyzed transcripts could impede growth. Factors like low accuracy, specificity, repeatability, and precision of microarray setups, along with sensitivity to hybridization temperature variations, may affect customer preferences. Additionally, the dependence on pre-existing genomic sequence data limits the flexibility of microarrays.
A notable trend shaping the market is the integration of omics technologies. This involves combining microarray analysis with advancements like bioinformatics and Next-Generation Sequencing (NGS) for more comprehensive data interpretation. Market leaders, Illumina and SomaLogic, recently signed a co-development agreement to enhance the SomaScan Proteomics Assay using Illumina's high-NGS platforms, promising deeper insights into genomics.
Product & Service Insights: Consumables Segment Leads in 2022
In 2022, the consumables segment dominated the global microarray analysis market, holding the largest revenue share. This segment's growth is attributed to the widespread usage of microarray technology across various industries and frequent large-scale consumable purchases. Plastic, glass, cover, and functionalized glass slides are essential consumables for gene scanning steps, further driven by the increasing number of research institutes, diagnostic labs, and rising methylation research in mRNA and DNA.
Application Insights: Research Applications and Disease Diagnostics Fuel Growth
The research application segment is anticipated to witness steady revenue growth during the forecast period, driven by increased public and private funding for genomics and proteomics research. Notable collaborations, like the USD 18 million funding by Genomics Canada and Genomics British Columbia in 2020, support advancements in diagnosis across various disorders, including cancer and Alzheimer's disease.
The disease diagnostics segment is expected to account for a significantly large revenue share due to microarray analysis enabling the detection and characterization of genetic variants associated with diseases. This high-throughput method aids in early identification, precise diagnosis, and personalized treatment plans, with microarray-based disease diagnostics evolving rapidly.
End-Use Insights: Research & Academic Institutes Lead the Way
The research & academic institutes segment is projected to experience the fastest revenue growth, driven by increased microarray usage in drug Research & Development (R&D) applications. Collaborations between Illumina Inc. and prominent research institutes underline the instrumental role of microarrays in understanding genetic factors causing various disorders.
Pharmaceutical and biotechnology companies are expected to hold the largest revenue share, given the strategic acquisitions aimed at expanding product portfolios. For instance, Thermo Fischer Scientific Inc.'s acquisition of Affymetrix in 2019 reinforces the importance of microarray chips in genetic variation and gene expression investigations.
Regional Insights: North America Dominates, Asia Pacific Shows Strong Growth
North America led the global microarray analysis market in 2022, attributing its largest revenue share to the presence of large companies, rising disease prevalence, and innovative research devices. Asia Pacific is poised for the fastest revenue growth, fueled by increasing cancer prevalence, rising chronic illnesses, and investments in precision medicine. Noteworthy is China's substantial investment of USD 9 billion in precision medicine, driving demand for microarray analysis.
Europe is expected to account for a considerable revenue share, driven by increased investments and the rising prevalence of cancers, as highlighted by data from the European Society for Medical Oncology (ESMO). Venture capital initiatives in biotechnology companies further contribute to the region's market growth.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/2628
Scope of Research
Report Details | Outcome |
Market Size in 2022 | USD 4.90 Billion |
CAGR (2023–2032) | 9.0% |
Revenue Forecast To 2032 | USD 11.55 Billion |
Base Year For Estimation | 2022 |
Historical Data | 2019–2021 |
Forecast Period | 2023–2032 |
Quantitative Units | Revenue in USD Billion and CAGR in % from 2023 to 2032 |
Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments Covered | Product & service, type, application, end-use, and region |
Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Country Scope | U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Benelux, Russia, Rest of Europe, China, India, Japan, South Korea, ASEAN Countries, Oceania, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, and Rest of Middle East & Africa |
Key Companies Profiled | Illumina, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Merck KgaA, PerkinElmer, Inc., Arrayit Corporation, Bio-Rad Laboratories, Inc., GE Healthcare, Molecular Devices, LLC., Affymetrix, RayBiotech Life, Inc., Full Moon BioSystem, Inc., CapitalBio Technology Co., Ltd., Microarray Inc., and QIAGEN |
Customization Scope | 10 hours of free customization and expert consultation |
Major Companies and Competitive Landscape
The global microarray analysis market is fairly fragmented with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective microarray analysis products in the market.
Some major players included in the global microarray analysis market report are:
- Illumina, Inc.
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Merck KGaA
- PerkinElmer, Inc.
- Arrayit Corporation
- Bio-Rad Laboratories, Inc.
- GE Healthcare
- Molecular Devices, LLC.
- Affymetrix
- RayBiotech Life, Inc.
- Full Moon BioSystem, Inc.
- CapitalBio Technology Co., Ltd.
- Microarray Inc.
- QIAGEN
Strategic Development
- In January 2023, Agilent Technologies, Inc. introduced the SureSelect Human All Exon V9, a new microarray platform. This platform provided scientists with a cutting-edge method for thorough genetic analysis, making it possible to quickly and precisely identify genetic variants linked to various diseases. The SureSelect Human All Exon V9 microarray has significantly accelerated research in fields including population genetics, uncommon genetic disorders, and oncology owing to its comprehensive perspective of the human exome.
- In November 2021, Illumina, Inc. and Seqll Inc., a creator of cutting-edge sequencing technologies, established a strategic partnership. This partnership aimed to improve long-read sequencing capabilities by fusing SeqLL's exclusive Long-Read Sequencing technology with Illumina's sequencing through microarray devices. This collaboration aims to overcome problems in genomic research and make it possible for scientists to better understand intricate biological systems.
Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/2628
Segments Covered in Report
For the purpose of this report, Emergen Research has segmented the global microarray analysis market on the basis of product & service, type, application, end-use, and region:
- Product & Service Outlook (Revenue, USD Billion; 2019-2032)
- Consumables
- Instruments
- Software and Services
- Type Outlook (Revenue, USD Billion; 2019-2032)
- DNA Microarray
- Deoxyribonucleic Acid (cDNA) Microarray
- Bacterial Artificial Chromosome (BAC) Microarray
- Single Nucleotide Polymorphism (SNP) Microarray
- Oligo Microarray
- Protein Microarray
- Analytical Protein Microarray
- Functional Protein Microarray
- Reverse-Phase Protein Microarray
- Peptide Microarray
- DNA Microarray
- Application Outlook (Revenue, USD Billion; 2019-2032)
- Research Applications
- Drug Discovery
- Disease Diagnostics
- Other Applications
- End-use Outlook (Revenue, USD Billion; 2019-2032)
- Research & Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Diagnostic Laboratories
- Other End Use
- Regional Outlook (Revenue, USD Billion; 2019–2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Benelux
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- ASEAN Countries
- Oceania
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- Israel
- Turkey
- South Africa
- Rest of Middle East & Africa
- North America
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/microarray-analysis-market
Curated Reports You Shouldn't Miss: Dive In Now!
Electronic Skin Patches Market By Component, By Application, By End-Users, Forecasts to 2027
Electronic Medical Records Market Analysis By Product Type (Inpatient EMR, Outpatient EMR), By Component (Software, Services, Others), By Application (Hospitals, Clinics, Ambulatory Surgical Centers, Others), By Region, Forecast to 2027
Gut Microbiome Test Market Analysis By Product Type (Gut Microbiome Testing Kit, Others), By Application (Homecare Settings, Hospitals, Clinics & Laboratories, Others), By Region, Forecast to 2027
Predictive Biomarkers Market, By Indication (Cancer, Neurological Disorders, Cardiovascular Disorders, Immunological Disorders, and Others), By End-Use, and By Region Forecast to 2030
Next Generation Implants (NGI) Market By Application (Orthopedic Implants, Cardiovascular Implants, Ocular Implants, Dental Implants, Others), By Material (Metals and Metal Alloys, Ceramics, Polymers, Biologics, Others), By End-Use (Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics, Academic and Research Institutes), By Region Forecast to 2028
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights